Jaguar Health, Inc. (NASDAQ:JAGX) Sees Large Increase in Short Interest

Jaguar Health, Inc. (NASDAQ:JAGX) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 430,700 shares, an increase of 29.6% from the October 31st total of 332,300 shares. Based on an average daily volume of 266,600 shares, the days-to-cover ratio is currently 1.6 days. Currently, 5.6% of the shares of the stock are short sold.

Institutional Investors Weigh In On Jaguar Health

An institutional investor recently bought a new position in Jaguar Health stock. Perritt Capital Management Inc purchased a new position in Jaguar Health, Inc. (NASDAQ:JAGX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned approximately 0.51% of Jaguar Health as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 12.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Jaguar Health from a “sell” rating to a “hold” rating in a research note on Friday, September 13th.

Jaguar Health Price Performance

Shares of JAGX traded down $0.02 during mid-day trading on Monday, reaching $1.02. The company had a trading volume of 19,880 shares, compared to its average volume of 716,576. Jaguar Health has a fifty-two week low of $0.90 and a fifty-two week high of $24.30. The firm has a fifty day simple moving average of $1.12 and a 200-day simple moving average of $2.37. The company has a quick ratio of 1.36, a current ratio of 1.84 and a debt-to-equity ratio of 1.65.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.